We are live on
!
Find out more
E Fund Management Portfolio holdings
AUM
$4.46B
Turnover
13.19%
This Fund
S&P 500
This Quarter
Est. Return
+29.65%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.58B
AUM Growth
+$264M
(+20%)
Cap. Flow
-$56.9M
Cap. Flow
% of AUM
-3.61%
Top 10 Holdings %
Top 10 Hldgs %
70.28%
Holding
330
New
38
Increased
107
Reduced
155
Closed
24
Avg Time Held
1.8
years
Top 10 Avg Time Held
0.8
years
Top 20 Avg Time Held
1.4
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
JOYY Inc
JOYY
|
+$3.5M |
| 2 |
Weibo
WB
|
+$2.7M |
| 3 |
iShares Core S&P 500 ETF
IVV
|
+$1.76M |
| 4 |
Hesai Group
HSAI
|
+$1.67M |
| 5 |
Structure Therapeutics
GPCR
|
+$1.64M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
STAAR Surgical
STAA
|
+$23.4M |
| 2 |
Yum China
YUMC
|
+$14M |
| 3 |
TSMC
TSM
|
+$8.84M |
| 4 |
Pinduoduo
PDD
|
+$8.79M |
| 5 |
Apple
AAPL
|
+$4.77M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 50.26% |
| 2 | Technology | 23.48% |
| 3 | Communication Services | 8.85% |
| 4 | Real Estate | 5.2% |
| 5 | Healthcare | 4.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
151
Vaxcyte
PCVX
$10B
| $532K | 0.03% |
8,476
+60
| +0.7% | +$3.12K |
2022 Q4
4 quarters
|
|
152
Sarepta Therapeutics
SRPT
$1.81B
| $532K | 0.03% |
5,519
+1,705
| +45% | +$164K |
2022 Q1
7 quarters
|
|
153
Exelixis
EXEL
$15.4B
| $524K | 0.03% |
21,832
+1,150
| +6% | +$25K |
2021 Q4
8 quarters
|
|
154
TG Therapeutics
TGTX
$8.26B
| $522K | 0.03% |
30,553
-13,457
| -31% | -$156K |
2021 Q4
8 quarters
|
|
155
Natera
NTRA
$56.7B
| $517K | 0.03% |
8,260
-177
| -2% | -$8.84K |
2022 Q1
7 quarters
|
|
156
Immunovant
IMVT
$5.52B
| $516K | 0.03% |
12,256
-2,989
| -20% | -$110K |
2022 Q4
4 quarters
|
|
157
Alkermes
ALKS
$6.92B
| $515K | 0.03% |
18,573
+2,723
| +17% | +$70.7K |
2022 Q1
7 quarters
|
|
158
CDW
CDW
$18.8B
| $514K | 0.03% |
2,262
+1,044
| +86% | +$221K |
2021 Q1
11 quarters
|
|
159
PACCAR
PCAR
$58.3B
| $512K | 0.03% |
5,244
-505
| -9% | -$45.4K |
2021 Q1
11 quarters
|
|
160
GE HealthCare
GEHC
$31.4B
| $507K | 0.03% |
6,556
+294
| +5% | +$20.6K |
2023 Q2
2 quarters
|
|
161
Intellia Therapeutics
NTLA
$1.6B
| $505K | 0.03% |
16,551
+4,476
| +37% | +$129K |
2022 Q1
7 quarters
|
|
162
Arista Networks
ANET
$223B
| $502K | 0.03% |
8,524
-584
| -6% | -$30.7K |
2021 Q1
11 quarters
|
|
163
Carnival Corporation Ltd
CCL
$34.8B
| $501K | 0.03% |
+27,038
| New | +$393K |
2023 Q4
0 quarters
|
|
164
PTC Therapeutics
PTCT
$4.94B
| $501K | 0.03% |
18,188
+7,589
| +72% | +$174K |
2022 Q1
7 quarters
|
|
165
Amphenol
APH
$196B
| $501K | 0.03% |
20,200
-1,464
| -7% | -$32.3K |
2021 Q1
11 quarters
|
|
166
DELISTED
Nuvalent
NUVL
| $500K | 0.03% |
6,798
+1,883
| +38% | +$117K |
2023 Q3
1 quarter
|
|
167
CrowdStrike
CRWD
$233B
| $500K | 0.03% |
7,836
-696
| -8% | -$36.4K |
2021 Q3
9 quarters
|
|
|
MRTX
168
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $500K | 0.03% |
8,503
-4,320
| -34% | -$243K |
2022 Q1
7 quarters
|
|
169
Ionis Pharmaceuticals
IONS
$7.14B
| $499K | 0.03% |
9,865
-1,231
| -11% | -$59K |
2022 Q1
7 quarters
|
|
170
BioMarin Pharmaceuticals
BMRN
$10.6B
| $498K | 0.03% |
5,168
+98
| +2% | +$8.67K |
2022 Q1
7 quarters
|
|
171
Beam Therapeutics
BEAM
$2.42B
| $495K | 0.03% |
18,174
+704
| +4% | +$17.5K |
2022 Q1
7 quarters
|
|
172
DELISTED
Immunogen Inc
IMGN
| $488K | 0.03% |
16,443
-12,682
| -44% | -$253K |
2021 Q1
11 quarters
|
|
173
Ross Stores
ROST
$75.7B
| $470K | 0.03% |
3,394
-355
| -9% | -$44.2K |
2021 Q1
11 quarters
|
|
174
Syndax Pharmaceuticals
SNDX
$1.15B
| $466K | 0.03% |
21,580
+6,986
| +48% | +$107K |
2022 Q3
5 quarters
|
|
175
Copart
CPRT
$25.8B
| $465K | 0.03% |
9,494
-855
| -8% | -$40.4K |
2021 Q1
11 quarters
|
|
Similar funds
E Fund Management's Q4 2023 Portfolio in Review
As of Q4 2023, E Fund Management held 330 positions worth $1.58B, up 20% from $1.31B the previous quarter. Its ten largest holdings account for 70% of the portfolio.
E Fund Management withdrew a net $56.9M in Q4 2023, closing 24 positions and reducing 155 holdings. Its most notable exit was MINISO, an estimated $2.17M position sold in full.
By sector, the portfolio is most concentrated in Consumer Discretionary at 50% of assets, up from 45% a quarter earlier, followed by Technology and Communication Services.
Against the trend, E Fund Management opened a new position in Hesai Group worth $1.52M.
- E Fund Management's largest Q4 2023 buy was Hesai Group: 170,914 shares worth $1.52M.
- E Fund Management added most to JOYY Inc in Q4 2023, an estimated $3.5M increase.
- E Fund Management's biggest Q4 2023 reduction was STAAR Surgical, cutting an estimated $23.4M.
- E Fund Management fully exited MINISO in Q4 2023, selling an estimated $2.17M.
- E Fund Management's ten largest holdings make up 70% of its $1.58B portfolio in Q4 2023.
- E Fund Management opened 38 new positions and closed 24 in Q4 2023.
- E Fund Management's portfolio value rose 20% quarter-over-quarter to $1.58B.
Based on E Fund Management's 13F filing for Q4 2023, filed 7 Feb 2024.